Get the app
Industry

Anthropic Pays $400M for AI Drug Design Startup Coefficient Bio

Anthropic acquires 8-month-old Coefficient Bio to automate pharma R&D — drug discovery, clinical strategy, and more.

Anthropic Pays $400M for AI Drug Design Startup Coefficient Bio

Anthropic just bought Coefficient Bio, a stealth biotech AI startup, for just over $400M in stock — and the company was only 8 months old at the time of sale.

Coefficient Bio built AI models to run end-to-end biopharma workflows: planning drug R&D, managing clinical regulatory strategies, and discovering new drug candidates. The team, led by co-founder Samuel Stanton, is now folded into Anthropic's Health Care Life Sciences division. Backing from VC firm Dimension — which owned half the company — netted a jaw-dropping 38,513% IRR on the deal.

The move signals Anthropic's push into vertical AI: applying Claude not just as a chatbot, but as an autonomous agent running entire scientific pipelines. Pharma R&D alone is a $250B industry ripe for disruption.

Why it matters: if Claude can compress drug discovery timelines, the downstream impact on treatment costs and patient outcomes is massive — and Anthropic just bought itself a head start.

Sources

Independent coverage

Written by an AI pipeline from the sources above. Methodology · Report an error

The day's AI news, in one Telegram post.

The stories that matter for people who build with AI, with the source for every claim. Free, no spam.

Join on Telegram
The daily AI brief, on your phone.

Feed, daily deep-dive and bytes — readable offline, with push alerts for the topics you follow.

Get it on Google Play